PT3830085T - Derivados deuterados do lanifibranor - Google Patents

Derivados deuterados do lanifibranor

Info

Publication number
PT3830085T
PT3830085T PT197596588T PT19759658T PT3830085T PT 3830085 T PT3830085 T PT 3830085T PT 197596588 T PT197596588 T PT 197596588T PT 19759658 T PT19759658 T PT 19759658T PT 3830085 T PT3830085 T PT 3830085T
Authority
PT
Portugal
Prior art keywords
lanifibranor
deuterated derivatives
deuterated
derivatives
Prior art date
Application number
PT197596588T
Other languages
English (en)
Original Assignee
Inventiva
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inventiva filed Critical Inventiva
Publication of PT3830085T publication Critical patent/PT3830085T/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/428Thiazoles condensed with carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PT197596588T 2018-07-27 2019-07-26 Derivados deuterados do lanifibranor PT3830085T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1857021A FR3084254B1 (fr) 2018-07-27 2018-07-27 Derives deuteres du lanifibranor

Publications (1)

Publication Number Publication Date
PT3830085T true PT3830085T (pt) 2024-01-24

Family

ID=63684156

Family Applications (2)

Application Number Title Priority Date Filing Date
PT197596588T PT3830085T (pt) 2018-07-27 2019-07-26 Derivados deuterados do lanifibranor
PT232014589T PT4331584T (pt) 2018-07-27 2019-07-26 Utilizações terapêuticas de derivados deuterados do lanifibranor

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT232014589T PT4331584T (pt) 2018-07-27 2019-07-26 Utilizações terapêuticas de derivados deuterados do lanifibranor

Country Status (19)

Country Link
US (2) US12291526B2 (pt)
EP (2) EP4331584B1 (pt)
JP (2) JP7434278B2 (pt)
CN (1) CN112638911B (pt)
DK (2) DK4331584T3 (pt)
ES (2) ES2970597T3 (pt)
FI (2) FI3830085T3 (pt)
FR (1) FR3084254B1 (pt)
HR (2) HRP20250340T8 (pt)
HU (2) HUE070489T2 (pt)
LT (2) LT3830085T (pt)
MA (1) MA67726B1 (pt)
MD (1) MD4331584T2 (pt)
PL (2) PL4331584T3 (pt)
PT (2) PT3830085T (pt)
RS (2) RS65095B1 (pt)
SI (2) SI4331584T1 (pt)
SM (2) SMT202400053T1 (pt)
WO (1) WO2020021215A1 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102199640B1 (ko) * 2020-01-06 2021-01-07 브렉소젠 주식회사 라니피브라노르를 포함하는 줄기세포 유래 엑소좀 생성 촉진 및 줄기세포기능 강화용 조성물
EP4000616A1 (en) 2020-11-17 2022-05-25 Inventiva Combination therapy for the treatment of a liver disease
WO2022143479A1 (zh) * 2020-12-29 2022-07-07 广东东阳光药业有限公司 一种化合物的固体形式及其制备方法和用途
KR20240047402A (ko) * 2021-08-12 2024-04-12 크리스탈 파마슈티컬 (쑤저우) 씨오., 엘티디. 라니피브라노르의 결정형, 이의 제조 방법 및 이의 용도
CN120857930A (zh) 2023-01-19 2025-10-28 伊文蒂瓦公司 拉尼兰诺制剂
KR20260020956A (ko) 2023-06-05 2026-02-12 엥방티바 간 질환을 가진 환자의 내장 혈관 확장증의 치료에 사용하기 위한 라니피브라노르
KR20260016549A (ko) 2023-06-06 2026-02-03 엥방티바 라니피브라노르를 이용한 간 질환 치료를 모니터링하기 위한 아디포넥틴, 페리틴, mmp9 및 트랜스페린의 용도
WO2024252162A1 (en) 2023-06-06 2024-12-12 Inventiva Use of ck18m65, hyaluronic acid, fructosamine and alt for monitoring of liver disease treatment with lanifibranor
WO2025061927A1 (en) 2023-09-22 2025-03-27 Inventiva Method of making lanifibranor
WO2025132989A1 (en) 2023-12-21 2025-06-26 Inventiva Combination therapy for the prevention and/or the treatment of a liver disease
WO2025132955A1 (en) 2023-12-21 2025-06-26 Inventiva Combination therapy for the prevention and/or the treatment of a liver disease
TW202543596A (zh) 2024-03-15 2025-11-16 法商因文帝華公司 預防接受過氧化物酶體增生劑活化受體(ppar)促效劑治療患者之血液病症
WO2025191292A1 (en) 2024-03-15 2025-09-18 Inventiva Methods and monitoring of treatment with lanifibranor

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2890071B1 (fr) 2005-08-30 2007-11-09 Fournier Sa Sa Lab Nouveaux composes de l'indole
JP6557684B2 (ja) 2014-06-13 2019-08-07 インベンティバ 線維性疾患の治療に用いられるppar化合物
WO2017136375A1 (en) 2016-02-05 2017-08-10 Concert Pharmaceuticals, Inc. Deuterated tozadenant
WO2018039521A1 (en) 2016-08-26 2018-03-01 Concert Pharmaceuticals, Inc. Deuterated cenicriviroc
US11504380B2 (en) * 2019-11-08 2022-11-22 Inventiva Method of treatment of cirrhosis

Also Published As

Publication number Publication date
FI3830085T3 (fi) 2024-01-17
DK3830085T3 (da) 2024-01-22
HUE065045T2 (hu) 2024-04-28
EP4331584B1 (fr) 2025-01-01
FR3084254B1 (fr) 2020-10-23
SI3830085T1 (sl) 2024-03-29
HRP20250340T8 (hr) 2025-06-20
DK4331584T3 (da) 2025-03-17
ES2970597T3 (es) 2024-05-29
CN112638911B (zh) 2024-07-19
SMT202400053T1 (it) 2024-03-13
HRP20250340T1 (hr) 2025-05-09
HRP20240157T1 (hr) 2024-04-12
LT4331584T (lt) 2025-03-25
FI4331584T3 (fi) 2025-04-01
JP7637281B2 (ja) 2025-02-27
WO2020021215A1 (fr) 2020-01-30
SMT202500113T1 (it) 2025-05-12
RS66614B1 (sr) 2025-04-30
ES3014955T3 (en) 2025-04-28
LT3830085T (lt) 2024-02-12
SI4331584T1 (sl) 2025-04-30
US20210300913A1 (en) 2021-09-30
US20250263406A1 (en) 2025-08-21
EP3830085B1 (fr) 2023-11-08
PL3830085T3 (pl) 2024-04-15
EP4331584A1 (fr) 2024-03-06
JP2021533101A (ja) 2021-12-02
EP3830085A1 (fr) 2021-06-09
US12291526B2 (en) 2025-05-06
CN112638911A (zh) 2021-04-09
HUE070489T2 (hu) 2025-06-28
RS65095B1 (sr) 2024-02-29
JP7434278B2 (ja) 2024-02-20
MA67726B1 (fr) 2025-04-30
FR3084254A1 (fr) 2020-01-31
PT4331584T (pt) 2025-02-27
PL4331584T3 (pl) 2025-04-28
MD4331584T2 (ro) 2025-11-30
JP2024036611A (ja) 2024-03-15

Similar Documents

Publication Publication Date Title
SMT202400053T1 (it) Derivati deuterati del lanifibranor
IL272888B1 (en) Uses of piperidinyl-indole derivatives
HUE070725T2 (hu) Odevixibat kristálymódosulatai
PL3645518T3 (pl) Synteza omekamtywu mekarbilu
IL276592A (en) History of Subtirum
PT3661491T (pt) 3-metilmetcatinona para uso no tratamento de um indivíduo sob uma intervenção psicoterapêutica
GB2573065B (en) Optimization of ranging measurements
SG11202012594RA (en) Spirochromane derivatives
LT3796975T (lt) Sulfonilaminobenzamido dariniai
SG11202106009TA (en) Deuterated analogs of acetyl-leucine
PL3770162T3 (pl) Pochodne dihydrochromenu
ZA202105399B (en) Use of spiropidion
ZA202104656B (en) Deuterated forms and derivatives of volinanserin
SG11202105136WA (en) Application of chidamide
SG11202101817UA (en) Methods of inhibition
PT3901141T (pt) Nova forma de isoquinolinossulfonamida
HK40054945A (en) Deuterated analogs of acetyl-leucine
GB201820685D0 (en) Synthesis of 8-chloroadenosine derivatives
GB201810835D0 (en) Methods of use
IL260405A (en) None-abusive derivatives of ritalin
GB201807468D0 (en) Methods of synthesis
GB201806948D0 (en) Derivatives
GB201721386D0 (en) Chrondogy of time-wave
PT3511335T (pt) Fabrico de metalassilsesquioxanos